Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells

被引:45
作者
Almind, K
Ambye, L
Urhammer, SA
Hansen, T
Echwald, SM
Holst, JJ
Gromada, J
Thorens, B
Pedersen, O
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Hagedorn Res Inst, Copenhagen, Denmark
[3] Univ Copenhagen, Dept Med Physiol, Copenhagen, Denmark
[4] Novo Nordisk AS, Dept Islet Cell Physiol, Copenhagen, Denmark
[5] Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland
关键词
Type II diabetes mellitus; generics; GIP receptor; mutations; incretins; C-peptide response; transfections;
D O I
10.1007/s001250051051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The two incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are insulinotropic factors released from the small intestine to the blood stream in response to oral glucose ingestion. The insulinotropic effect of GLP-1 is maintained in patients with Type II (non-insulin-dependent) diabetes mellitus, whereas, for unknown reasons, the effect of GIP is diminished or lacking. We defined the exon-intron boundaries of the human GIP receptor, made a mutational analysis of the gene and identified two amino acid substitutions, A207 V and E354Q, In an association study of 227 Caucasian Type II diabetic patients and 224 matched glucose tolerant control subjects, the allelic frequency of the A207 V polymorphism was 1.1 % in Type II diabetic patients and 0.7 % in control subjects (p = 0.48), whereas the allelic frequency of the codon 354 polymorphism was 24.9 % in Type II diabetic patients versus 23.2 % in control subjects, Interestingly, the glucose tolerant subjects (6 % of the population) who were homozygous for the codon 354 variant had on average a 14 % decrease in fasting serum C-peptide concentration (p = 0.01) and an 11 % decrease in the same variable 30 min after an oral glucose load (p = 0.03) compared with subjects with the wild-type receptor. Investigation of the function of the two GIP receptor variants in Chinese hamster fibroblasts showed, however. that the GIP-induced cAMP formation and the binding of GIP to cells expressing the variant receptors were not different from the findings in cells expressing the wild-type GIP receptor. Tn conclusion, amino acid variants in the GIP receptor are not associated with random Type II diabetes in patients of Danish Caucasian origin or with altered GIP binding and CIP-induced cAMP production when stably transfected in Chinese hamster fibroblasts. The finding of an association between homozygosity for the codon 354 variant and reduced fasting and post oral glucose tolerance test (OGTT) serum C-peptide concentrations, however, calls for further investigations and could suggest that GIP even in the fasting state regulates the beta-cell secretory response.
引用
收藏
页码:1194 / 1198
页数:5
相关论文
共 10 条
[1]   AMINO-ACID POLYMORPHISMS OF INSULIN-RECEPTOR SUBSTRATE-1 IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
ALMIND, K ;
BJORBAEK, C ;
VESTERGAARD, H ;
HANSEN, T ;
ECHWALD, S ;
PEDERSEN, O .
LANCET, 1993, 342 (8875) :828-832
[2]   Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide [J].
Ding, WG ;
Gromada, J .
DIABETES, 1997, 46 (04) :615-621
[3]  
GREMLICH S, 1995, DIABETES, V44, P1201
[4]   The pathogenesis of NIDDM involves a defective expression of the GIP receptor [J].
Holst, JJ ;
Gromada, J ;
Nauck, MA .
DIABETOLOGIA, 1997, 40 (08) :984-986
[5]   DIMINISHED IMMUNOREACTIVE GASTRIC-INHIBITORY POLYPEPTIDE RESPONSE TO A MEAL IN NEWLY DIAGNOSED TYPE-I (INSULIN DEPENDENT) DIABETICS [J].
KRARUP, T ;
MADSBAD, S ;
MOODY, AJ ;
REGEUR, L ;
FABER, OK ;
HOLST, JJ ;
SESTOFT, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (06) :1306-1312
[6]   Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM - No evidence of association with Japanese NIDDM subjects [J].
Kubota, A ;
Yamada, Y ;
Hayami, T ;
Yasuda, K ;
Someya, Y ;
Ihara, Y ;
Kagimoto, S ;
Watanabe, R ;
Taminato, T ;
Tsuda, K ;
Seino, Y .
DIABETES, 1996, 45 (12) :1701-1705
[7]   PRESERVED INCRETIN ACTIVITY OF GLUCAGON-LIKE PEPTIDE-1 [7-36 AMIDE] BUT NOT OF SYNTHETIC HUMAN GASTRIC-INHIBITORY POLYPEPTIDE IN PATIENTS WITH TYPE-2 DIABETES-MELLITUS [J].
NAUCK, MA ;
HEIMESAAT, MM ;
ORSKOV, C ;
HOLST, JJ ;
EBERT, R ;
CREUTZFELDT, W .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) :301-307
[8]  
Thorens B, 1995, DIABETES METAB, V21, P311
[9]  
WIDMANN C, 1994, MOL PHARMACOL, V45, P1029
[10]   HUMAN GASTRIC-INHIBITORY POLYPEPTIDE RECEPTOR - CLONING OF THE GENE (GIPR) AND CDNA [J].
YAMADA, Y ;
HAYAMI, T ;
NAKAMURA, K ;
KAISAKI, PJ ;
SOMEYA, Y ;
WANG, CZ ;
SEINO, S ;
SEINO, Y .
GENOMICS, 1995, 29 (03) :773-776